Sector Chart Summit Therapeutics Inc.

Equities

SMMT

US86627T1088

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 18:16:35 10/02/2026 GMT			5-day change	1st Jan Change
15.41 ^USD	+2.94%		+6.07%	-11.52%

01-29	Sector Update: Health Care Stocks Edge Higher Premarket Thursday	MT
01-29	Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy	CI

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes

Sector Bio Therapeutic Drugs

	Capi.	Sales growth	Profitability	Finances	EV / Sales	P/E
SUMMIT THERAPEUTICS INC.	11.54B	-	-	-	-	-
ARGENX SE	51.1B
WUXI APPTEC CO., LTD.	42.55B
INSMED INCORPORATED	31.89B					-
BIONTECH SE	27.69B					-
WUXI BIOLOGICS (CAYMAN) INC.	20.25B